Newleos Therapeutics Appoints Timothy Noyes as President and CEO

• Newleos Therapeutics has appointed Timothy Noyes as President and Chief Executive Officer, succeeding founding CEO David Donabedian, who will continue as an advisor.

• The company aims to advance its pipeline of therapies for generalized anxiety disorder, social anxiety disorder, and substance use disorders, building on recent Series A financing of $93.5 million.

Newleos Therapeutics, a clinical-stage biotechnology company developing treatments for neuropsychiatric disorders, has named Timothy Noyes as its new President and Chief Executive Officer. Mr. Noyes succeeds founding CEO David Donabedian, who will remain with the company in an advisory role.

Mr. Noyes brings over 30 years of experience leading biopharmaceutical companies through early- and late-stage development and commercialisation. His prior roles include CEO positions at Aerovate Therapeutics and Proteon Therapeutics, where he successfully guided companies through IPOs and advanced clinical programmes. Earlier in his career, he held senior leadership roles at GelTex Pharmaceuticals and Genzyme, and began his career in commercial roles at Merck.

As CEO, Mr. Noyes will oversee Newleos’ development of first-in-class and best-in-class therapies for high-unmet-need mental illnesses, including generalized anxiety disorder, social anxiety disorder, and substance use disorders. “I am thrilled to join Newleos as President and CEO. The company is at a pivotal inflection point, translating strong science into clinical momentum across programs that could redefine how anxiety and related disorders are treated,” said Mr. Noyes.

The leadership transition follows Newleos’ founding in early 2025, the completion of an oversubscribed $93.5 million Series A financing, and the initiation of two clinical studies for its GABAA-γ1 selective positive allosteric modulator, NTX1955, as well as FDA IND clearance for its brain-penetrant V1a receptor antagonist, NTX-1472. Executive Chair Christoph Westphal highlighted Mr. Noyes’ track record in company building and advancing clinical programmes as critical for guiding Newleos into its next stage of growth.

David Donabedian is acknowledged for securing high-quality clinical assets from Roche, establishing the company’s leadership team, closing its Series A financing, and forming a clinical advisory board of neuropsychiatric experts. His ongoing advisory role will support Mr. Noyes and the continued development of Newleos’ neuropsychiatric pipeline.